Tetra Bio-Pharma Inc. is pleased to announce that all matters presented for approval at the Corporation’s annual general and special meeting of shareholders of the Corporation held in Montréal, province of Québec, on June 20, 2019, were approved.
Stay up to Date
With our deep technical expertise, innovative approach and proven track-record, we are truly invested in bringing novel drugs and treatments to patients and their healthcare providers.
Stay up-to-date with the latest news and information from Tetra Bio-Pharma, its subsidiaries and its partners by reading press releases, getting the latest updates on product development and finding out about upcoming events.
Register for email alerts and be the first to have Tetra’s news delivered to your inbox.
Tetra Bio-Pharma Inc. is pleased to announce that it has filed and received a receipt for a preliminary short form prospectus in connection with a proposed offering of units for minimum gross proceeds of C$3,500,000 and maximum gross proceeds of C$7,000,000.
Tetra Bio-Pharma Inc. is pleased to provide investors with an update on our research, regulatory and commercial activities. This market update covers Tetra and its subsidiaries, Panag and Tetra Natural Health (TNH).
Carol Levine (Energi PR)
Tel: 514.288.8500, ext. 226